

REMARKS

Any fees that may be due in connection with filing this paper, or during the entire pendency of this application, may be charged to Deposit Account No. 06-1050.

The specification is amended to correct obvious and minor typographical, spelling and grammatical errors. Examples of typographical errors corrected include elimination of redundant phrases or words, errors in subscripts or abbreviations, and use of symbols. Common grammatical errors corrected include noun and verb agreement, proper use of articles, and agreement in word tense. In addition, the words "also is" were inadvertently inserted in the middle of words and phrases. Thus, the specification has been corrected to remove each of the instances in which this occurred (page 145, line 10; page 149, line 9; and 169, lines 10 and 11).

The amendment of the paragraph on page 1, line 9 removes "each of" in that reference is only being made to one provisional application. The amendment of the paragraph on page 1, line 10, incorporates the now available International Application Number "PCT/US03/20959" assigned to the application entitled "NUCLEIC ACID MOLECULES ENCODING SERINE PROTEASE 16, THE ENCODED PROTEINS AND METHODS BASED THEREON" filed on July 2, 2003 as Attorney Docket No. 24745-1625PC as defined in the original application. Provided herewith as evidence, a copy of the Notification of the International Application Number and the International Filing Date mailed February 23, 2004 in which the proper International Application Number is identified.

The amendment of the paragraph on page 5, line 27 through page 6, line 6 amends the redundancy by removing the phrase "...of the this protein..."

The amendment of the paragraph on page 8, lines 13-25 adds the word "anitbodies" to the phrase on line 23 "...can be used to produce that bind to..." such that it now reads as "...can be used to produce antibodies that bind to..." This change finds basis on page 8, lines 22-24 in which it reads "...as well as

single-chain protease-specific antibodies and/or multi-chain specific antibodies." From this portion of the sentence it can be logically inferred that the agents binding to single and/or multi-chain forms are antibodies. Basis may also be found on page 10, lines 19-21 and in the examples on page 147, lines 11-13.

The amendment of the paragraph on page 10, line 19, through page 11, line 5, replaces the phrase on line 22 "...single-specific antibodies..." with "...single-chain specific antibodies..." This amendment finds basis on page 10, lines 19-21 in which the specification explains how antibodies may recognize single chain or double chain forms of the protein or protease domain.

The amendment of the paragraph on page 12, lines 8-18, removes the second instance of the sentence on lines 13-18 that reads, "The CVSP16 polypeptides (including those that include....in a substrate therefor, or a cofactor." This is a word-for-word repeat of the previous sentence on lines 8-13.

The amendment of the paragraph on page 12, lines 19-24, replaces the phrase on line 24 "...above a predetermined among is a body fluid..." with "...above a predetermined level in a body fluid..." This amendment finds basis in the phrase on page 58, lines 3-5 which reads "...a CVSP16 polypeptide...is detectable in a body fluid at a level that differs from its level in body fluids...".

The amendment of the paragraph on page 28, lines 3-13, adds the word "any" to the phrase on line 12 "...refers to form in which..." such that it now reads as "...refers to any form in which..." This amendment finds basis in the previous sentence of the same paragraph which reads "...two-chain protease domain form refers to any form in which..." The phrases further define the two-chain and three-chain protease domain forms. This amendment also finds basis on page 56, lines 28-30 in which it reads "...three chain forms, the activated full-length or truncated forms thereof, such as forms in which the signal peptide is removed..." indicating the presence of multiple forms and providing support for the use of the word "any".

The amendment of the paragraph on page 50, line 22 through page 51, line 3 removes the phrase on lines 22-24 that reads "...procedures using conditions of moderate stringency include...but are not limited to..." This phrase is redundant when read together with the following phrase which reads "...procedures using such conditions of moderate stringency are as follows..."

The amendment of the paragraph on page 52, lines 17-29 adds the noun "molecule" after the adjective "full-length" to the phrase on line 26 such that the phrase now reads as "...form of the full-length molecule." This amendment finds basis on page 52, line 23 which reads "...to the full-length molecule, such as the zymogen form..."

The amendment of the paragraph on page 70, line 30, through page 71, line 4 adds the inadvertently omitted letter "f" and replaces the phrase on line 31 "...of any of a)-), where..." with "...of any of a)-f), where..." This amendment finds basis on page 70, line 24 in which it reads "...of any of a)-f), where..." such that the phrase correctly points to the above-identified polypeptides of items a, b, c, d, e, and f.

The amendment of the paragraph on page 116, lines 21-25, add the word "forms" to the phrase on line 22 that reads "...three-chain thereof." This amendment finds basis, for example, on page 18, line 14. Single chain, two chain, and three chain "forms" are described throughout the specification.

The amendment of the paragraph on page 117, lines 4-13 replaces the number "1" with the number "2" when describing "protease domain 2 (PD2)." The amendment finds basis in the sentence on lines 8-9 in which protease domain 1 is abbreviated "PD1" and also in claim 63 which reads "...protease domain 2 (PD2) of a CVSP16 polypeptide."

The amendment of the paragraph on page 148, line 25-30 removes the redundancy in the phrase reading "...in known *in vivo* and *in vivo* systems..." by replacing the second instance of the phrase *in vivo* and adding "*in vitro*". This amendment finds basis on page 45, lines 14-19 in which it reads "...Biological

activity, thus, encompasses therapeutic effects and pharmaceutical activity of such compounds, compositions and mixtures. Biological activities can be observed in *in vitro* systems designed to test or use such activities."

Upon entry of the amendment, 121 claims will be pending. Claims 3, 11, 12, 14, 15, 19, 28, 30, 47, 55, 61, 62, 64, 66, 85 and 117 are amended. Claims 11, 12, 14, 15, 19, 28, 30, 47, 55, 61, 62, 66 and 117 are amended to correct minor typographical, grammatical and spelling errors. New claims 119-121 are added. Basis for the new claims is found in the specification as originally filed on page 6, lines 19-23 and on page 54, lines 20-22.

The typographical error in claim 3 has been corrected to replace the phrase on line 23 which reads as "...amino acids 47-286 of SEQ ID No. 6..." with "...amino acids 46-286 of SEQ ID No. 6..." The amendment finds basis on page 7, lines 1-5 and page 25, lines 19 and 21 as well as in Claim 3, line 22. These instances among other identify the protease domain of SEQ ID No. 6 as being amino acids 46-286.

The typographical error in claim 64 has been corrected to replace the phrase "An antibody of the specifically that binds..." with "An antibody that specifically binds..." This amendment finds basis in Claim 63 in the phrase on line 28 "An antibody that specifically binds..."

The typographical error in claim 85 has been corrected to add the inadvertently omitted noun —portion— to the phrase on line 21 which reads "...functionally active thereof,..." such that the phrase reads as "...functionally active portion thereof,..." This amendment finds basis in Claim 85 in the phrase on line 23 "...or a functionally active portion thereof..."

No new matter has been added.

Applicant: Madison, et. al
Serial No.: 10/612,466
Filed: July 1, 2003
Preliminary Amendment


17106-037001(24745-1625)

* * *

Entry of this amendment and examination of the application are respectfully requested.

Respectfully submitted,

By:


Stephanie L. Seidman
Registration No. 33,779

Dated: July 16, 2004

Attorney Docket No. 17106-037001 / 1625

Address all correspondence to:

Stephanie L. Seidman
Fish & Richardson, P.C.
12390 El Camino Real
San Diego, California 92130
Telephone: (858) 678-4777
Facsimile: (202) 626-7796
Email: seidman@fr.com